Coherus is a promising company that did a bad borrowing and has more than paid the price. Its convertible bondholders created a short hedge and have inflicted massive damage on the company's SP.Read more
Coherus Oncology bets on newer, more targeted cancer medicines and wider use of its lead therapy beyond major hospitals, which could surprise the market if adoption spreads faster than expected. The catch is that progress depends on a small number of drug programs, so trial setbacks, tougher competition, or rising costs could quickly derail the story.Read more
A cancer drug maker could get a major shift in its outlook as new trial results arrive and its lead treatment starts gaining traction with more doctors. But it’s also a crowded race, and the business depends heavily on just a few products and partners—so setbacks could hit hard.Read more
Coherus Oncology looks like a high-stakes cancer drug story: it has promising programs, but it leans heavily on a small handful of late-stage treatments that still need the right trial results and approvals. Competition, tougher insurance coverage, and slower-than-hoped doctor adoption could keep the business from turning its science into lasting sales.Read more
No trending discussion available.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
